Chronic myelogenous leukemia imatinib mesylate

Imatinib Mesylate (Gleevec) Tyrosine kinase inhibitor bcr-abl, c-kit Chronic myelogenous leukemia Hematologic and cytogenetic response rate. Phase III GIST ... 

Cohen, M.H. et al.. Approval summary for Imatinib Mesylate capsules in the treatment of chronic myelogenous leukemia, Clin. Can. Res., 8, 935-942, 2002. 

Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. Y EnglJMed 2002 346 645-652. 

Ulmer T, Schaich M, Platzbecker U et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004 18 401 08. 

Donato N, Wu J, Kong LY et al. Constitutive activation of SRC-family kinases in chronic myelogenous leukemia patients resistant to imatinib mesylate in the absence of BCR-ABL mutations a rationale use of SRC/ABL dual kinase inhibitor-based therapy (Abstract 1087). B/oo<7 2005 106 316a. 

Nicolini FE, Corm S, Le QH et al. Mutation status and elinieal outeome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients a retrospeetive analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 2006 20 1061-1066. 

Kantarjian HM, Talpaz M, O Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003 101 473 75. 

Johnson JR, Bross P, Cohen M, et al. Approval summary Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res 2003 9 1972-1979. 

Imatinib mesylate was the first tyrosine kinase inhibitor to be approved for treatment of cancer (see Table 124—18). It inhibits deregulated bcr-abl tyrosine kinase, the molecular abnormality in patients with chronic myelogenous leukemia that results from the characteristic Philadelphia chromosome translocation. The deregulated tyrosine kinase constantly drives leukemic cell proliferation. Imatinib inhibits cell proliferation and induces apoptosis in the Philadelphia chromosome-positive cells. It is relatively, but not completely, selective for these cells. °°... 

Kantarjian H, Talpaz M, O Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myelogenous leukemia. Blood 2004 103 2873-2878. 

Kantarjian HM, O Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002 100 1590-1595. 

Breccia M, Muscaritoli M, Averaa Z, K delli F, Alimena G. Imatinib mesylate may im Tove fasting blood glucose in diabetic F1i+ chronic myelogenous leukemia patients re nsive to treatment. J Clin Oncol (2004) 22,4653-55. 

States, acrivastine (18) is the active ingredient in the Semprex-D brand. Imatinib mesylate (Gleevec, 19) is a tyrosine kinase inhibitor and was approved for the treatment of ten different cancers including chronic myelogenous leukemia (CML) by 2001. Atazanavir (Reyataz, 20) is a once-daily, anti-viral drug of the protein kinase class, and, it is prescribed for human immunodeficiency virus (HIV). 

Among small-molecule TKIs, one of the more successful agents is imatinib mesylate. Imatinib mesylate is a TKI of the fusion oncoprotein Bcr-Abl, a gene product driving the development of chronic myelogenic leukemia (CML). A major reason for the effectiveness of Imatinib is CML transformation in many instances only requires Bcr-Abl. In these cases inhibition of Bcr-Abl activity is sufficient to provide long-term control of the disease. Solid tumors usually have multiple abnormal... 

Chu S, Holtz M, Gupta M et al. (2004) BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 103 3167-3174... 

Gefitinib is a tyrosine kinase inhibitor used in the treatment of refractory non-small cell carcinoma of the lung. Respiratory failure has been observed in 1 % of the cases with a 30% fatality rate and corresponds histologically to DAD with possible progression to fibrosis (4). Diffuse alveolar hemorrhage has also been reported. Rare cases of pulmonary complications with imatinib mesylate (used in chronic myelogenous leukemia) have also been described. 

---